Dinu Sen, CEO and Member of The Board
Dinu worked with a number of pharmaceutical companies, including Abbott Laboratories, Amgen, PathoGenesis, Cubist, Corus and Avera. As an officer of PathoGenesis and Corus, he was part of the team that sold the company to Chiron/Novartis and Gilead respectively. As CEO of Avera Pharmaceuticals he raised $90 million, took three products into clinical trials and sold the company to Maruishi Pharmaceuticals of Osaka, Japan. He is a Fellow of the Institute of Chartered Accountants of England and Wales and holds a Masters in Management (MBA) from the J. L. Kellogg School of Business at Northwestern University, Evanston, Illinois. He was the President of The South Coast chapter of TiE, the world’s largest organization devoted to entrepreneurship.
Robert Attiyeh, Member of The Board
Bob served as Senior Vice President, Finance and Corporate Development and as Chief Financial Officer of Amgen from 1994 to 1998. He was a Director of McKinsey and Company from 1967 to 1994, where he was active in the Scandinavian, Japan and Los Angeles offices. He has served on the Board of Directors of International Rectifier Corporation since 2003, served as a Director of The Federal Reserve Bank of San Francisco (1987 to 1993) and on the Board of Myraid Genetics (2003 to 2009). Bob holds a masters degree in business administration from Harvard University and an electrical engineering degree from Cornell University.
Bernard King, MD, MBA, Chief Medical Officer
Dr. King has more than 25 years’ experience managing business and development operations in the pharmaceutical industry. He has directed development programs for more than 100 pharmaceutical, medical device and biologics products. Prior positions have included: Sen. VP, Development at Kemia, VP and GM for San Diego Operations for PAREXEL; VP Worldwide Medical and Regulatory Affairs, a BristolMyers Squibb subsidiary; and, Director of Clinical Investigation at SmithKline. Dr. King received his MD from the Ohio State Univ. College of Medicine. Following completion of residency training in Medicine and Pathology and his Cardiology fellowship training at the Mt. Sinai Medical Center in New York, he was an Assistant Professor in Medicine (Cardiology) and Physiology at New York Medical College. He is board certified in Cardiology and Internal Medicine. He received his MBA from the Wharton School of the Univ. of Pennsylvania.
Paula Adams, PhD, Vice President of Regulatory Affairs
Paula joined CURx as Vice President of Regulatory Affairs in September 2014. She has over 25 years of experience in drug development in the biotechnology and pharmaceutical industries, including leadership roles in Regulatory Affairs and Quality Assurance. Most recently, Paula was Senior Vice President of Regulatory Affairs & Compliance at Anthera Pharmaceuticals. Previously, she was Vice President of Regulatory Affairs & Quality Assurance at OXiGENE. Prior to that, Paula held various scientific, quality and regulatory positions at PathoGenesis, Amgen, SkyePharma and Anesiva. Paula has a B.A. in Natural Sciences from Johns Hopkins University and a Ph.D. in Toxicology from University of North Carolina.
Richard Johnson, Vice President of Manufacturing
Richard has over 35 years of experience in pharmaceutical synthesis and Drug Product transfer from research through clinical and commercial manufacturing at Burroughs Wellcome, Mallinckrodt and Avera Pharmaceuticals. At Mallinckrodt he had issued patents on API synthesis and prefilled Ultrajet syringes and led the team that developed and introduced an improved synthesis of the ioversol API for the X-Ray contrast agent Optiray in 55 countries. Richard has a degree in Chemical Engineering and Masters of Business Administration.
Eric Gruff
Dr Gruff has spent 30 years working in the Pharmaceutical industry. He has worked for larger companies like Pfizer and smaller companies like Agouron in the manufacturing quality assurance and quality control areas. He has contributed to the manufacturing and development of several products including Calquence, Zydelig, Sutent, Viracept, and Contrave. For the last 10 years, he has consulted for venture capital and smaller companies.